175 related articles for article (PubMed ID: 36658256)
1. Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer.
Lindfors H; Karlsen M; Karlton E; Zedenius J; Larsson C; Ihre Lundgren C; Juhlin CC; Shabo I
Sci Rep; 2023 Jan; 13(1):1070. PubMed ID: 36658256
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid Cancer.
Lindfors H; Ihre Lundgren C; Zedenius J; Juhlin CC; Shabo I
World J Surg; 2021 Jul; 45(7):2155-2164. PubMed ID: 33825961
[TBL] [Abstract][Full Text] [Related]
3. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.
Back K; Kim TH; Lee J; Kim JS; Choe JH; Oh YL; Cho A; Kim JH
J Pediatr Surg; 2023 Mar; 58(3):568-573. PubMed ID: 35973863
[TBL] [Abstract][Full Text] [Related]
4. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
[TBL] [Abstract][Full Text] [Related]
5. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
[TBL] [Abstract][Full Text] [Related]
6. Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model.
Guo P; Wang X; Xia L; Shawureding N; Hu Z
Cancer Med; 2023 Apr; 12(7):7868-7876. PubMed ID: 36560883
[TBL] [Abstract][Full Text] [Related]
7. How Many Nodes to Take? Lymph Node Ratio Below 1/3 Reduces Papillary Thyroid Cancer Nodal Recurrence.
Weitzman RE; Justicz NS; Kamani D; Kyriazidis N; Chen MH; Randolph GW
Laryngoscope; 2022 Sep; 132(9):1883-1887. PubMed ID: 35229306
[TBL] [Abstract][Full Text] [Related]
8. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
9. Lymph node ratio independently associated with postoperative thyroglobulin levels in papillary thyroid cancer.
Hei H; Luo Z; Zheng C; Gong W; Zhou B; Fang J; Qin J
Oral Oncol; 2023 Nov; 146():106563. PubMed ID: 37690364
[TBL] [Abstract][Full Text] [Related]
10. Thyroglobulin Determination in Fine Needle Aspiration Biopsy Washout of Suspicious Lymph Nodes in Thyroid Carcinoma Follow up.
Achille G; Garrisi VM; Russo S; Guastamacchia E; Giagulli VA; Schirosi L; Daniele A; Tufaro A; Cafagna V; Centrone M; Simone G; Abbate I; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2017; 17(3):213-218. PubMed ID: 28558632
[TBL] [Abstract][Full Text] [Related]
11. Lymph node ratio predicts recurrence in papillary thyroid cancer.
Schneider DF; Mazeh H; Chen H; Sippel RS
Oncologist; 2013; 18(2):157-62. PubMed ID: 23345543
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
13. Lymph node ratio in lateral neck is an independent risk factor for recurrence-free survival in papillary thyroid cancer patients with positive lymph nodes.
Luo Z; Hei H; Qin J; Zheng C; Gong W
Endocrine; 2022 Dec; 78(3):484-490. PubMed ID: 36018538
[TBL] [Abstract][Full Text] [Related]
14. The Value of Ki-67 Labeling Index in Central Lymph Node Metastasis and Survival of Papillary Thyroid Carcinoma: Evidence From the Clinical and Molecular Analyses.
Lei Y; Zhao X; Feng Y; He D; Hu D; Min Y
Cancer Control; 2023; 30():10732748231155701. PubMed ID: 36744396
[TBL] [Abstract][Full Text] [Related]
15. The utility of lymph node mapping sonogram and thyroglobulin surveillance in post thyroidectomy papillary thyroid cancer patients.
Miah CF; Zaman JA; Simon M; Davidov T; Trooskin SZ
Surgery; 2014 Dec; 156(6):1491-6; discussion 1496-7. PubMed ID: 25456939
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma.
Vas Nunes JH; Clark JR; Gao K; Chua E; Campbell P; Niles N; Gargya A; Elliott MS
Thyroid; 2013 Jul; 23(7):811-6. PubMed ID: 23373961
[TBL] [Abstract][Full Text] [Related]
17. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
18. Cervical Lymph Node Fine-Needle Aspiration and Needle-Wash Thyroglobulin Reflex Test for Papillary Thyroid Carcinoma.
Zhang X; Howell JM; Huang Y
Endocr Pathol; 2018 Dec; 29(4):346-350. PubMed ID: 30203321
[TBL] [Abstract][Full Text] [Related]
19. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
20. Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size.
Kim HI; Kim TH; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim YN; Kim H; Ahn HS; Kim K; Kim SW; Chung JH
Cancer Med; 2017 Oct; 6(10):2244-2251. PubMed ID: 28857489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
